Vis enkel innførsel

dc.contributor.authorWaldock, Joanna
dc.contributor.authorRemarque, Edmond J.
dc.contributor.authorZheng, Lingyi
dc.contributor.authorHo, Sammy
dc.contributor.authorHoschler, Katja
dc.contributor.authorNeumann, Britta
dc.contributor.authorSediri-Schön, Hanna
dc.contributor.authorTrombetta, Claudia M.
dc.contributor.authorMontomoli, Emanuele
dc.contributor.authorMarchi, Serena
dc.contributor.authorLapini, Giulia
dc.contributor.authorZhou, Fan
dc.contributor.authorJalloh, Sarah Larteley Lartey
dc.contributor.authorCox, Rebecca Jane
dc.contributor.authorFacchini, Marzia
dc.contributor.authorCastrucci, Maria Rita
dc.contributor.authorFriel, Damien
dc.contributor.authorOllinger, Thierry
dc.contributor.authorCaillet, Catherine
dc.contributor.authorMusic, Nedzad
dc.contributor.authorPalladino, Giuseppe
dc.contributor.authorEngelhardt, Othmar G.
dc.date.accessioned2023-10-06T12:58:56Z
dc.date.available2023-10-06T12:58:56Z
dc.date.created2023-06-20T12:37:25Z
dc.date.issued2023
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11250/3094986
dc.description.abstractIntroduction: The haemagglutination inhibition assay (HAI) and the virus microneutralisation assay (MN) are long-established methods for quantifying antibodies against influenza viruses. Despite their widespread use, both assays require standardisation to improve inter-laboratory agreement in testing. The FLUCOP consortium aims to develop a toolbox of standardised serology assays for seasonal influenza. Building upon previous collaborative studies to harmonise the HAI, in this study the FLUCOP consortium carried out a head-to-head comparison of harmonised HAI and MN protocols to better understand the relationship between HAI and MN titres, and the impact of assay harmonisation and standardisation on inter-laboratory variability and agreement between these methods. Methods: In this paper, we present two large international collaborative studies testing harmonised HAI and MN protocols across 10 participating laboratories. In the first, we expanded on previously published work, carrying out HAI testing using egg and cell isolated and propagated wild-type (WT) viruses in addition to high-growth reassortants typically used influenza vaccines strains using HAI. In the second we tested two MN protocols: an overnight ELISA-based format and a 3-5 day format, using reassortant viruses and a WT H3N2 cell isolated virus. As serum panels tested in both studies included many overlapping samples, we were able to look at the correlation of HAI and MN titres across different methods and for different influenza subtypes. Results: We showed that the overnight ELISA and 3-5 day MN formats are not comparable, with titre ratios varying across the dynamic range of the assay. However, the ELISA MN and HAI are comparable, and a conversion factor could possibly be calculated. In both studies, the impact of normalising using a study standard was investigated, and we showed that for almost every strain and assay format tested, normalisation significantly reduced inter-laboratory variation, supporting the continued development of antibody standards for seasonal influenza viruses. Normalisation had no impact on the correlation between overnight ELISA and 3-5 day MN formats.en_US
dc.language.isoengen_US
dc.publisherFrontiersen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleHaemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.articlenumber1155552en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3389/fimmu.2023.1155552
dc.identifier.cristin2156165
dc.source.journalFrontiers in Immunologyen_US
dc.identifier.citationFrontiers in Immunology. 2023, 14, 1155552.en_US
dc.source.volume14en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal